Best of ASCO® Toronto 2024: Melanoma – Dr. Sam Saibil
OR
Co-Chairs
Dr. Aly-Khan Lalani
Dr. Natasha Leighl
Speakers
Dr. Sam Saibil
This program has been made possible through unrestricted support from Ipsen
Studies/trials discussed:
- Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
- Neo-Adjuvant Immunotherapy: The Rationale
- Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study.
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
- djuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
